Evaluation of the Reliability and Validity of the Persian Version of Urticaria Control Test (UCT) by Khoshkhui, Maryam et al.
Copyright © 2021 Khoshkhui et al. Published by Tehran University of Medical Sciences.      423 
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International license (https://creativecommons.org/licenses/  
by-nc/4.0/). Non-commercial uses of the work are permitted, provided the original work is properly cited. 
ORIGINAL ARTICLE 
Iran J Allergy Asthma Immunol 
August 2021; 20(4):423-431. 
Doi: 10.18502/ijaai.v20i4.6952 
 
Evaluation of the Reliability and Validity of the Persian Version  
of Urticaria Control Test (UCT) 
 
Maryam Khoshkhui1, Karsten Weller2, Javad Fadaee3, Marcus Maurer2, Farahzad Jabbari Azad1,  
and Maryam Emadzadeh4 
 
1 Allergy Research Center, Mashhad University of Medical Sciences, Mashhad, Iran 
2 Dermatological Allergology, Department of Dermatology and Allergy, Allergie-Centrum-Charité,  
Charité – Universitätsmedizin Berlin, Berlin, Germany  
3 Department of Pediatrics, Faculty of Medicine, Shahrekord University of Medical Sciences, Shahrekord, Iran 
4 Clinical Research Development Unit, Ghaem Hospital, Mashhad University of Medical Sciences, Mashhad, Iran 
 





The urticaria control test (UCT) is a patient-reported outcome measure (PROM) for chronic 
urticaria (CU) patients. As a Persian version of the UCT was not available, the present research 
aimed to develop such a version, to test its reliability and validity as well as to evaluate urticaria 
control among Persian-speaking patients. 
This research was conducted at the Urticaria Centre of Reference and Excellence (UCARE) 
of Ghaem Hospital, Mashhad, Iran. In a first step, a linguistically validated Persian version of the 
UCT was developed through a structured forward and backward translation process and 
subsequent cognitive debriefing interviews. In a second step, the Persian version of the UCT was 
completed by 100 well-characterized CU patients together with two anchor instruments, the 
Chronic Urticaria Quality of life Questionnaire (CU-Q2oL) and the urticaria activity score (UAS), 
to obtain information on its internal consistency reliability and convergent validity. 
The Persian version of the UCT was found to have acceptable internal consistency reliability 
with a Cronbach's alpha coefficient of 0.68. In addition, the results obtained with the Persian 
UCT correlated with the CU-Q2oL total score (-0.48, p<0.001) and the UAS (-0.404, p˂ 0.001), 
suggesting convergent validity. Virtually all patients had poorly controlled CU (UCT<12).  
A Persian version of the UCT is now available and may help to improve the assessment and 
monitoring of disease control in Persian-speaking CU patients and to optimize treatment 
decisions.  
 




Urticaria presents as a red, itchy rash consisting of 
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wheals, angioedema, or both. If urticaria lasts for more 
than 6 weeks, it is regarded as chronic urticaria (CU). 
CU affects about one percent of the total population.1,2 
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Treatment of CU is still challenging despite the 
availability of very effective and non-sedating 
antihistamines, omalizumab, treatment guidelines, and 
tools for monitoring treatment responses.3 
The signs and symptoms of CU are usually short-
lived and vary considerably from day to day. This 
unpredictable nature of CU makes it difficult for 
treating physicians to get a reliable picture of the 
patient’s current disease status and to decide about the 
best treatment approach. Accordingly, there is a need 
for instruments to reliably evaluate the patient’s disease 
status and to monitor disease control over time, e.g. 
before and after treatment adjustments. Within the past 
years, different patient-reported outcome measures 
(PROMs) were developed to assess disease activity, 
quality of life impairment, and disease control. They 
are useful clinical instruments to monitor CU 
patients.4,5 Among them are the Urticaria Activity 
Score (UAS),2 the Chronic Urticaria Quality of Life 
Questionnaire (CU-Q2oL),5 the urticaria severity score 
(USS),6,7 and the urticaria control test (UCT).8 
The current international guideline for urticaria 
suggests the use of the UAS and CU-Q2oL as PROMs 
to evaluate CU.9 However, both PROMs suffer several 
limitations, including the fact that they can be used 
only for patients with chronic spontaneous urticaria but 
not for patients with chronic inducible urticaria. 
Moreover, the UAS only works prospectively, and the 
scoring of the CU-Q2oL is often too complicated in 
routine patient care. 
The UCT is a retrospective PROM that consists of 
only 4 questions. Accordingly, it is easy to administer, 
easy to complete, and easy to score. It determines the 
current level of disease control and provides 
information on whether the current treatment is 
sufficient or not.8 Treatment of CU is aimed to achieve 
the absence of signs and symptoms, i.e. complete 
disease control, and to minimize disease burden with a 
well-tolerated therapy.2,8 The UCT may help to achieve 
this treatment goal if applied continuously over time. 
The UCT was originally developed and published 
in 2014 in German. It can be used in all adult patients 
with any type of CU and has a recall period of 4 weeks. 
Its 4 questions have 5 answer options each that are 
scored from 0 to 4. Accordingly, the UCT score can 
reach between 0 and 16 points with higher scores 
indicative of a higher level of disease control. In the 
original publication of the UCT, a cut-off value of 12 
points was identified with ≥12 points indicating well-
controlled CU and<12 points indicating poorly 
controlled disease. 
The present research aimed to develop a validated 
Persian version of the UCT. Also, it aimed to 
investigate the level of disease control in Persian CU 
patients as well as to identify and characterize subjects 
with poorly-controlled disease. 
 
MATERIALS AND METHODS 
 
Translation and Linguistic Validation of the Persian 
Version of the UCT 
Two independent forward translations of the 
German version of the UCT were performed by two 
native Persian-speakers bilingual in German. Some 
minor differences between the two forward translations 
were resolved with the translators with the result of a 
consolidated Persian version of the UCT. Then, 
backward translations to Persian were performed by 
two independent German native bilingual speakers. The 
backward translations were checked against the 
original German version by the original author of the 
UCT, and inconsistencies were discussed and resolved 
with the Iranian team with the result of a final Persian 
translation of the UCT. 
As a last step of the linguistic validation process, a 
cognitive debriefing was performed. To this end, the 
final Persian translation of the UCT was provided to 10 
CU patients. The purpose of this step was to evaluate 
the clarity of the instructions, all questions and answer 
options as perceived by the patients as well as to make 
sure that the patient’s perception of the items is equal 
to the intended content. 
 
Validity and Reliability Analyses 
To further test the validity and reliability of the 
Persian version of the UCT, it was handed out to 100 
consecutive CU patients of the Urticaria Center of 
Reference and Excellence10 at the Ghaem Hospital in 
Mashhad, Iran, from November 2017 to April 2018, 
together with the CU-Q2oL and the UAS as anchor 
instruments. 
Before participation, all subjects were asked to 
provide informed consent. All procedures of the study 
were explained and patients' demographic information 
was collected including age, gender, duration of the 
disease, and the presence or absence of angioedema. 
Furthermore, the autologous serum skin test (ASST) 
was performed. 
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Internal Consistency Reliability 
To test the internal consistency reliability of the 
Persian version of the UCT, Cronbach's alpha 
coefficient was computed. A coefficient between 0.6 
and 0.7 is commonly interpreted as acceptable; a 
coefficient between 0.7 and 0.9 is interpreted as  




To test the convergent validity of the UCT, its 
results were correlated with the results of the two 
anchor instruments, the CU-Q2oL as well as the UAS. 
Pearson correlation coefficients of˂0.3, 0.3-0.6, 
and˃0.6 were interpreted as indicative of a weak, 
moderate, and strong correlation.11,13 
The CU-Q2ol is a disease-specific quality of life 
questionnaire for CU patients and consists of 23 items 
with a recall period of 2 weeks. Here, the Persian 
version of the CU-Q2oL was used.14 The achievable 
minimum and maximum total score of the CU-Q2oL 
was 23 and 115, respectively. The higher the score of 
the CU-Q2oL was, the higher the CU-related quality of 
life impairment was obtained. 
The UAS was used as an in-clinic assessment.15 To 
this end, the treating physician retrospectively rated, 
together with the patients, the daily intensity of wheals 
from 0 to 3 as well as the daily intensity of pruritus 
from 0 to 3 over 7 days. Also, the extent of itching is 
rated between 0 and 3. Accordingly, the achievable 
minimum and maximum UAS were 0 and 42, 
respectively. 
 
Autologous Serum Skin Test (ASST) 
To perform the ASST, under aseptic conditions, a 
sample of 5 cc blood was taken from the brachial vein 
and stored in a closed falcon test tube without any 
anticoagulant at room temperature for 30 minutes. 
Once full coagulation occurred, full segregation was 
done in a lab centrifuge at the speed of 2000 rpm for 10 
minutes. Insulin syringes were used for intradermal 
injection of 0.05 cc of the patient’s serum to the volar 
aspect of the forearm as well as to inject histamine and 
saline as positive and negative controls. After 30 
minutes, the test result was obtained. The ASST was 
regarded as positive when the wheal at the serum 
injected site was at least 1.5 mm larger than the wheal 
of the negative control.16 
 
Statistical Analyses 
All the statistical analyses were done in the 
Statistical Package for the Social Sciences software 
(SPSS.23), IBM Corporation, Armonk, NY, USA. 
Confirmatory factor analyses (CFA) were done by IBM 
SPSS AMOS 23.0.0. In the present research, a p˂0.05 
was regarded as significant. 
 
Ethical Issues 
In advance of the conduction of this research, all 
subjects were instructed on how to fill out the 
questionnaires and their informed consent to participate 
was obtained. They were ensured of the confidentiality 
of the information they provided, and that their 
participation had no interference with the medical staff 
care provision. The present research received the 
ethical code of IR.MUMS.fm.REC.1396.610 from the 






In the present research, 100 consecutive CU 
patients were included. The patient characteristics are 
summarized in Table 1. 
 
Internal Consistency of the Persian Version of the 
UCT 
All 100 CU patients fully completed the UCT. 
When interviewed subsequently, they were all found to 
have a similar conception and understanding of the 
items as originally indented and faced no problem 
filling out the questionnaire. 
The internal consistency reliability of the Persian 
version of the UCT was found to be acceptable with a 
Cronbach's alpha coefficient of 0.68. 
 
Convergent Validity of the Persian Version of the 
UCT 
The UCT score showed a moderate correlation with 
the CU-Q2oL total score (-0.48, p˂0.001) and a weak to 
moderate correlation with the UAS (-0.404, p˂0.001), 
suggesting moderate levels of convergent validity for 
the Persian version of the UCT. The correlation 
coefficients of the UCT and its subgroups with CU-
Q2oL total score are shown in Table 2. 
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Table 1. Chronic spontaneous urticaria (CSU) patients characteristics 
Subject characteristic % 
Gender  Female 66 
Age  ≤ 20 years 7 
21-40 years 61 
41-60 years 28 
>60 years 4 
Disease duration  ≤ 2 years 65 
2-10 years 31 
>10 years 4 
Angioedema 43 
ASST* Positive 58 
*ASST: Autologous Serum Skin Test; n = 100 
 
Table 2. Correlation between Chronic Urticaria Quality of Life Questionnaire (CU-Q2oL) total score and urticaria control 
test (UCT) scores; using Pearson correlation test 
Variable Correlation coefficient p 
First question -0.47 <0.001 
Second question -0.48 <0.001 
Third question -0.28 <0.005 
Fourth question -0.2 <0.048 
UCT total score -0.48 <0.001 
 
CFA was also run to test whether or not the 4 
questions of UCT identified cohered together into a 
single construct. The single-factor model [χ2/df 
ratio=0.169; CFI=1.00, TLI=1.00, SRMR=0.008, 
RMSE<0.0001] yielded excellent fit (Figure 1, Table 
3). 
 
CU Control in Persian-speaking Patients 
The mean UCT score±SD of all included patients 
was 5.3±2.0 (median: 5), indicating poorly controlled 
CU in most patients. Table 4 shows the frequency of 
the patient’s responses to the four UCT items. Only one 
patient achieved a UCT score of 12 points, indicative of 
a well-controlled CU. Figure 2 shows the proportion of 
patients achieving different possible UCT scores. 
 
Potential Patient Characteristics Influencing CU 
Control in Persian-speaking Patients 
The UCT results in patients with different 
characteristics are shown in Table 5. No major 
differences were found between patients of different 
gender, ages, disease duration, presence or absence of 
angioedema, and a negative or positive ASST result.
 
Table 3. Urticaria control test (UCT) single factor confirmatory factor analyses (CFA) model fit measures 
Measure Estimate Threshold Interpretation 
CFI 1.000 >0.95 Excellent 
TLI 1.000 >0.95 Excellent 
RMSEA 0.000 <0.06 Excellent 
CFI: comparative fit index; TLI: Tucker-Lewis index; RMSEA: Root mean square error of approximation 
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Figure 1. Single-factor confirmatory factor analyses (CFA) model.  
Note: Model-based on maximum likelihood (ML) estimations. All of the standardized coefficients are significant at the 0.05 
level. 
 
Table 4. Frequency of the Iranian patient’s responses to the four urticaria control test (UCT) items  
UCT items N (%) 
UCT item 1 - Physical discomfort due to CU*  
Very much 27 
Much 41 
Somewhat 28 
A little 4 
Not at all 0 
UCT item 2 – Quality of life impairment due to CU  
Very much 17 
Much 38 
Somewhat 34 
A little 11 
Not at all 0 
UCT item 3 – Treatment failure related to CU  
Always 27 
Very frequently 22 
Occasionally 30 
Rarely 17 
Very rarely 4 
UCT item 4 – Overall CU control  
Not at all 24 
A little 33 
Somewhat 31 
Much 12 
Very much 0 
*CU - chronic urticaria 
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Table 5. Urticaria control test (UCT) results in patients with different characteristics 
 Mean UCT score ± SD Median UCT score p 
Gender    
0.215* Female 5.03±2.74 5 
Male 5.76±2.86 5.5 
Age    
≤ 20 years 7.14±2.41 7 0.197** 
21-40 years 4.98±2.93 5  
41-60 years 5.28±2.27 5  
61-80 years 6.50±3.87 6.5  
Disease duration    
0- 2 years 5.52±2.73 6 0.362** 
2-10 years 4.8±2.62 4  
>10 years 5.00±4.96 4.5  
Angioedema   0.516* 
Yes  5.06±2.76 5  
No  5.43±2.82 5  
ASST   0.438* 
Positive 5.46±2.65 5  
Negative  5.02±2.99 4.5  













































Figure 2. The proportion of chronic spontaneous urticaria (CSU) patients achieving different urticaria control test (UCT)  
scores 
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DISCUSSION 
 
Here, we report the development of a validated Persian 
version of the UCT together with data on its internal 
consistency reliability and convergent validity as well 
as on potential factors that influence disease control. 
The use of the Persian UCT, for the first time, shows 
that virtually all patients with CU who were referred to 
UCARE of Ghaem Hospital, have poorly controlled 
disease.  
In our study, like in previous ones, the majority of 
patients presented with chronic urticaria of fewer than 2 
years duration,16-19 Also, CU was more prevalent 
among women and in the age group of 20-40 years, 
which again corresponds well to previous 
reports.13,16,20,21 Our finding that 43% of the patients 
presented with angioedema is consistent with the 
results of similar investigations. Other studies have also 
reported prevalence rates of about 40-50%.16,22,23 In our 
study population, 58 patients (58%) had a positive 
ASST. In previous studies, this value has been 
estimated at 40-60 percent.24,25 
Patients’ UCT scores correlated with disease 
activity as assessed by the UAS as well as the quality 
of life impairment, measured with the CU-Q2oL. This 
correlation refers to the internal consistency of the 
Persian version of the UCT and the suitability of its use 
in clinical trials and routine clinical practice. 
Correlations and Cronbach's alpha were somewhat 
weaker than those reported in other studies.11,19,26,27 
This could be due to different reasons, including 
cultural ones, affecting items of the UCT and the CU-
Q2oL. For example, people in Iran, especially women, 
usually cover all parts of their body in public and this 
may modify the patients’ reply to questions about 
embarrassment in public due to CU and types of 
selected clothes because they should routinely cover 
the affected parts and it may reduce their 
embarrassment. Additionally, it needs to be kept in 
mind that the tools for assessing the quality of life were 
not the same in all studies, e.g Nakatani et al, used the 
Dermatology Life Quality Index (DLQI)27 while we 
used CU-Q2oL. Another reason is that the UCT reflects 
a patient's judgment of disease control, which is linked 
to patients’ expectations regarding the outcome of their 
medical treatment. Expectations on the efficacy of 
treatment and the onset of improvement may differ 
between countries. There may also be country 
differences in the rates of patients who exaggerate or 
understate their disease situation. 
In this study, the mean UCT scores of virtually all 
patients showed poorly-controlled CU. The same result 
was found in previous studies in Iran.28,29 This is 
remarkable, but not surprising, as rates of uncontrolled 
CU are high globally.30,31 In the recent AWARE study, 
the proportion of patients with uncontrolled chronic 
spontaneous urticaria (UCT score <12) at baseline was 
78%.30 In the validation study of the UCT performed in 
Lebanon, the rate was 79%.26 It is noteworthy that our 
Urticaria Center of Reference and Excellence 
(UCARE), where this study was performed, is the only 
tertiary referral center in the northeast of Iran. Patients 
referred to our UCARE are often refractory to standard 
treatment, and most of them had experienced various 
previous unsuccessful treatment attempts. Thus, it is 
not surprising that the proportion of patients with 
poorly controlled CU is very high.2,8,11,19,26 
The strengths of this study include the use of the 
CU-Q2oL, which is designed specifically for patients 
with CU, and the fact that this study was performed by 
a single-center highly specialized in urticaria. The latter 
provides confidence that all patients included in this 
study had CU. Its limitations include the omission of 
analyses of test-retest reliability, responsiveness, and 
known-groups validity, all of which are well 
established and characterized, and that we did not 
include patients with chronic inducible urticaria.  
In conclusion, the UCT is a valuable tool that helps 
to assess the level of disease control and guide 
treatment decisions in CU patients. The Persian version 
of the UCT is now available and validated and may 
help to improve the assessment and monitoring of 
disease control in Persian-speaking CU patients as well 
as to optimize therapy. 
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